Genus plc / PIC
a CD163-exon deletion that blocks the PRRS virus's cell-entry point; approved by the FDA on April 30, 2025, and by Health Canada and the CFIA on January 23, 2026.
- Country
- United Kingdom
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| livestock-aqua | ✓ | ✓ | ✓ | ✓ |
Regulatorsfdacfiamoa-china
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Livestock genetic engineering and precision breeding | livestock-aqua | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.